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Abstract
Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. 
More  rarely  neoplasms  with  histology  and  immunohistochemistry  similar  to  GISTs  may  occur  outside  the  gastrointestinal  tract 
(  omentum, mesentery and retroperitoneum) and are so-called Extra-gastrointestinal Stromal Tumors (EGISTs).
EGISTs arising in the retroperitoneum are extremely rare: to date, only 58 cases have been reported in the literature.
Case report: We herein report a case of a primary EGIST of the retroperitoneum surgically treated. The pre-operative radiological 
evaluation showed a retroperitoneal mass, placed in left paravertebral region.
Results: Morphological and immunohistochemical features led to a diagnosis of extra-gastrointestinal stromal tumor (intermediate-low 
risk form).
Conclusions: As a result of the rarity of reports of primary EGISTs of retroperitoneum we need to analyze the data of reported cases in 
order to gain a better understanding about the pathogenesis, prognosis and optimal treatment of this disease.
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Introduction
The  gastrointestinal  stromal  tumors  (GISTs) 
represent less than 1% of all malignancies, but they 
are the most common mesenchymal neoplasms of the 
gastrointestinal tract.1–11
GIST arises from the wall of the gastrointestinal 
(GI)  tract  and  is  thought  to  originate  from  the 
Interstitial Cells of Cajal (ICC), which regulate the 
motility of the gastrointestinal tract.10,19–23
The  most  specific  and  important  immunohis-
tochemical  marker  is  the  KIT  (CD117)  protein,   
a tyrosine kinase growth factor receptor expressed in 
more than 95% of cases.4,7,10,16,23,24
The  gastrointestinal  tract  is  the  site  of  onset  of 
elective GIST: 40%–70% originates from the stomach, 
20%–40%  from  small  intestine,  5%–15%  from  the 
colon and rectum and 5% from the esophagus.10,15,25,26
More rarely neoplasms with histology and immu-
nohistochemistry similar to GISTs may occur outside 
the gastrointestinal tract (omentum, mesentery and ret-
roperitoneum) and are so-called Extra-gastrointestinal 
Stromal Tumors (EGISTs).4,10,12,15,18,25–32,58
Pathogenesis, incidence, clinicopathological   features 
and prognosis of EGISTs have not been   completely 
defined yet.4,13–15,18,27–32,58
EGISTs  arising  in  the  retroperitoneum  are 
extremely rare: to date there have been only 58 cases 
described  in  the  literature.4,12,15,18,27–29,33–35,58  These 
tumors are of general interest both in diagnosis and 
treatment.
Since the preoperative diagnosis based on clinical 
and radiological data is very difficult7,12,15,27,49–51 the 
patient undergoes a surgical operation for the generic 
diagnosis of “abdominal mass” which causes anxiety 
in both the surgeon and patient.
Surgical removal is the gold standard treatment for 
non-metastatic EGISTs and it is important to achieve 
a complete removal of the mass when possible “en 
bloc” with the contiguous tissues.7,11,15,48,53–55
The role of imatinib mesylate, which is the inhibi-
tor of the tyrosine kinase activity of KIT in the treat-
ment of EGISTs, is unclear.11,13,57,59
As a result of the rarity of reports of primary 
EGISTs of retroperitoneum it is necessary to analyze 
the data of reported cases in order to define clearly 
the phenotypic and genetic characteristics as well 
as the prognostic factors and the optimal treatment 
of these rare tumors.
We herein report a case of a primary EGIST of 
the retroperitoneum surgically treated and discuss its 
clinical behavior and treatment through a literature 
review.
case Report
A 39-year-old man was admitted to our institute for 
abdominal back pain present for 4 months, without 
any other sign or symptom. The pain over time has 
gradually increased in intensity and was treated with-
out benefit with analgesic drugs. Before admission, he 
underwent outpatient ultrasonography and abdominal 
computed tomography (CT) scan that showed a ret-
roperitoneal solid mass (60 × 60 × 80 mm), placed in 
left paravertebral region, level L3–L4, on the left side 
of aorta, ilio-psoas muscle adherent. No adenopathies 
or local infiltrations were found. The bowel was dis-
located without signs of intestinal occlusion (Fig. 1). 
The patient underwent CT-guided fine needle aspira-
tion (FNA) with the result of inadequate sampling of 
the mass lesion. As part of clinical and instrumental 
workup he underwent standard blood tests, electrocar-
diogram (ECG) and chest X-ray, the results of which 
were normal. The patient’s abdomen was normal and 
no mass was palpable. In view of patient’s charac-
teristics (a previous laparotomy for peritonitis due to 
acute appendicitis) and the dimension of the mass, an 
open procedure was preferred instead of laparoscopy 
approach. The laparotomy confirmed the presence of 
a solid and well defined mass located in the left para-
median region of the retroperitoneum. After section-
ing the parietal peritoneum in the transition from the 
left colon and sigmoid colon, the mass was gradually 
exposed  and  removed.  The  tumor  was  completely 
excised (R0 resection). No perioperative complica-
tions were recorded and the patient was discharged 
four  day  after  surgery.  Postoperative  pathologic 
evaluation revealed a 139—gram plurinodular mass, 
encapsulated, measuring 7.5 × 6 × 5.3 cm. After cut-
ting, the tissue appeared brownish—yellow in color 
and  had  elastic  consistency.  Microscopically  the 
tumor border was delineated from surrounding fat and 
no tumor cells were observed in the surgical   margin. 
  Microscopic  examination  also  showed    neoplastic 
proliferation composed by spindle cells type. Mitotic   
count  was  ,5  per  50  high-power  fields  (HPF) 
(low  mitotic  activity).  The  MIB-1  labelling  index 
(monoclonal antibody used to determine the Ki-67 eGIST of retroperitoneum
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labelling  index  that  is  correlated  with  the  clinical 
course  of  tumor)  was  3%–5%.  Immunohistochem-
istry showed positivity for KIT (CD 117) (Fig. 2), 
focal positivity for S-100 protein and NSE (neuron 
specific enolase), negativity for CD34, smooth and 
skeletal muscle actine. A molecular genetic analysis 
for KIT protein mutation was not performed due to 
its unavailability at our hospital. Morphological and 
immunohistochemical features leaded to a diagnosis 
of  gastrointestinal  stromal  tumor  which  d  imension 
Figure 1. Axial CT-scan shows a retroperitoneal mass (60 × 60 × 80 mm), solid, placed in left paravertebral region, level L3–L4, on the left side of aorta, 
ilio-psoas muscle adherent.
Figure 2. Immunohistochemically, the tumor cells test strongly positive for c-kit (×200).Casella et al
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and  number  of  mitosis  indicated  an  intermediate 
risk form according to risk assessment proposed by 
Fletcher et al16 and a low risk form according to the 
risk assessment proposed by Yamamoto et al.4 The 
further oncological evaluation did not consider nec-
essary an adjuvant therapy with imatinib mesylate 
because  the  tumor  was  completely  excised  (resec-
tion R0) and it was classified as an intermediated-low 
risk form. An abdominal CT scan did not show any 
recurrence of disease in the 2 years after surgery.
Discussion
The  GISTs  are  the  most  common  mesenchymal 
tumors of the gastrointestinal tract with an incidence 
estimated at 7 to 14 per 1 million in the general 
population.1–11,36,37 The discovery of the mutation of 
KIT (CD117) in GIST proto-oncogene was funda-
mental in order to understand the genesis and clas-
sification of these tumors.24 The fact that the cells of 
GISTs  show  ultrastructural  features  and  cellular 
markers, typical of Interstitial Cells of Cajal (ICC), 
has supported the hypothesis that they may originate 
from  these  cells.10,19–23  ICC  are  characterized  by 
expression of KIT (CD117).22 A subset of GISTs has 
mutation in the KIT-related kinase gene: platelet- 
derived growth factor receptor alpha (PDGFRA).39,40 
Proto-oncogene KIT mutations are found in more 
than  95%  of  GISTs,  and  in  5%–10%  of  cases 
mutations  of  the  PDGFRA  gene.4,7,10,16,23,24,38  The 
mutations mainly involving exon 11 of KIT gene are 
less frequently mutated exons 9, 13, 14 and 17 and 
exons 12 and 18 of PDGFRA gene.16,22,26 Mutations 
of KIT lead to a constitutional activation of tyrosine 
kinase function that determines resistance to cellular 
proliferation  and  apoptosis.23  KIT  and  PDGFRA 
mutations  appear  to  be  mutually  exclusive  onco-
genic  mechanisms  in  GISTs.39,40  It  is  not  clear 
whether the presence or absence of a mutation in the 
KIT or PDGFRA genes per se influences prognosis, 
although delections of the exon 11 have been linked 
to poor survival.16,22,26,41,42 Staining for other markers 
is more variable: BCL 2 80%, CD34 70%, muscle 
specific actin 50%, smooth muscle actine 35%, S100 
10% and desmin 5%.10,22,26 GISTs are usually com-
posed of a population of spindle cells (60%–70%) or 
epithelioid cells (20%) and the reminder consists of 
a mixture of these two morphologies.10,16,18,22,23 GISTs 
have been documented in all parts of the gastrointes-
tinal tract: especially in the stomach (60% to 70%) 
and small intestine (25% to 35%), with rare occur-
rence  in  the  colon  and  rectum  (5%),  esophagus 
(,2%)  and  appendix,  gallbladder  and  pancreas.10,15,25,26 
Some GISTs, primary in the omentum, mesentery or 
retroperitoneum, are unrelated to the tubular gastro-
intestinal tract and they are so-called Extra-gastroin-
testinal  Stromal  Tumor  (EGISTs).4,10,12,15,18,25–31,58 
EGISTs are identical by histological and immuno-
histochemical  features  with  GISTs.4,18,22,23,25,26,32,58 
However, incidence, histogenesis, clinical and prog-
nostic factors of EGISTs are not defined yet.4,13–15-
,18,27–32,58 EGISTs show staining of KIT, marker of 
Interstitial Cells of Cajal which are normally present 
just in the gut wall.4,18,27,32 The reason why this kind 
of cells, which normally are in the gut wall, can stay 
in the retroperitoneum, omentum or mesentery and 
originate a tumor is not clear yet. It can be hypoth-
esized  that  these  tumors  originate  from  common 
precursor cells which differentiate into the Intersti-
tial  Cells  of  Cajal  type  outside  from  the  gut 
wall.10,18,27,32,43,44 EGISTs are rare tumors. A total of 
99 omental and mesenteric EGISTs are reported in 
four  published  series  from  1999  to  2008.18,44–46 
EGISTs arising in the retroperitoneum are uncom-
mon. To date, only 58 cases of EGISTs of the retro-
peritoneum  have  been  reported  in 
Literature4,12,15,18,27–29,33–35,58 ( Table  1).  Reith  et  al18 
reported 48 cases of EGISTs and 6 of them origi-
nated in the retroperitoneum. 17 cases of EGSTs of 
the retroperitoneum have been reported by Yama-
moto et al4 and by Barreda Bolanos et al.15 These 
studies were frequently limited by the lack of infor-
mation available on clinical, pathological and prog-
nostic   features.27 The absence of specific symptoms 
associated with an objective, not always measurable, 
makes  difficult  an  early  diagnosis.  These  tumors 
grow silently and consequently they are discovered 
once they have reached a significant size, causing 
symptoms  of  compression.7,15,27  In  the  case  we 
reported, there were non-specific symptoms (poste-
rior abdominal pain) and there was no palpable mass 
on physical   examination. The CT-scan and MRI are 
the  standard  imaging  techniques  of  these 
tumors,7,12,47–51 but the preoperative diagnosis based 
on  radiological  data  is  very  difficult.12,49–51  Small 
tumors usually appear like a well-defined homoge-
neous mass, large tumors tend to be ill defined and eGIST of retroperitoneum
Clinical Medicine Insights: Oncology 2012:6  193
T
a
b
l
e
 
1
.
 
C
a
s
e
 
r
e
v
i
e
w
 
o
f
 
t
h
e
 
p
r
i
m
a
r
y
 
e
G
I
S
T
 
o
f
 
t
h
e
 
r
e
t
r
o
p
e
r
i
t
o
n
e
u
m
.
A
u
t
h
o
r
s
A
g
e
/
 
G
e
n
d
e
r
s
i
z
e
 
(
c
m
)
p
a
t
t
e
r
n
c
e
l
l
u
l
a
r
i
t
y
M
i
t
o
s
e
s
 
n
o
.
/
5
0
 
H
p
F
K
i
-
6
7
 
 
L
I
c
-
k
i
t
 
m
u
t
a
t
i
o
n
I
m
a
t
i
n
i
b
O
u
t
c
o
m
e
r
e
i
t
h
 
e
t
 
a
l
1
8
4
4
/
M
3
2
S
L
o
w
1
N
A
N
A
N
A
N
e
D
/
1
1
 
m
o
4
1
/
F
2
6
e
L
o
w
0
N
A
N
A
N
A
N
e
D
/
3
7
 
m
o
4
5
/
F
1
6
.
5
e
H
i
g
h
4
9
N
A
N
A
N
A
D
O
D
/
5
 
m
o
6
7
/
F
9
e
L
o
w
2
N
A
N
A
N
A
N
e
D
/
4
0
 
m
o
4
5
/
F
1
8
e
L
o
w
2
N
A
N
A
N
A
N
e
D
/
6
7
 
m
o
8
2
/
F
1
2
.
5
S
L
o
w
1
N
A
N
A
N
A
N
e
D
/
2
4
 
m
o
T
a
k
a
o
 
e
t
 
a
l
1
2
7
0
/
F
1
6
 
×
 
1
5
 
×
 
1
8
S
L
o
w
N
A
N
A
N
A
N
A
N
e
D
/
1
2
 
m
o
p
a
r
k
 
e
t
 
a
l
5
8
3
2
/
M
1
3
.
3
 
×
 
1
0
.
2
 
×
 
9
.
4
S
H
i
g
h
6
–
1
0
N
A
N
A
Y
e
s
N
e
D
/
6
 
m
o
F
e
r
c
h
i
c
h
i
 
 
e
t
 
a
l
3
4
5
4
/
M
1
0
S
N
A
6
N
A
N
A
N
A
N
A
T
a
k
i
z
a
w
a
 
 
e
t
 
a
l
3
5
6
7
/
M
3
.
7
 
×
 
5
.
5
S
N
A
1
0
–
1
5
3
–
5
N
A
N
A
N
e
D
/
1
8
 
m
o
Y
a
m
a
m
o
t
o
 
 
e
t
 
a
l
4
8
0
/
F
1
5
S
M
o
d
e
r
a
t
e
9
3
.
9
N
A
N
A
N
e
D
/
9
 
m
o
4
6
/
F
7
e
H
i
g
h
1
2
.
3
e
x
o
n
 
1
1
N
A
N
e
D
/
8
6
 
m
o
6
9
/
M
1
8
S
H
i
g
h
1
2
1
7
.
2
N
A
N
A
D
O
D
/
3
7
 
m
o
6
8
/
F
1
5
S
H
i
g
h
5
3
2
N
D
N
A
D
O
D
/
1
3
6
 
m
o
4
5
/
F
1
0
S
H
i
g
h
1
9
1
0
N
A
N
A
D
O
D
/
5
0
 
m
o
6
3
/
M
6
S
M
o
d
e
r
a
t
e
4
4
.
1
e
x
o
n
 
1
1
N
A
D
O
D
/
9
6
 
m
o
4
5
/
M
3
e
M
o
d
e
r
a
t
e
1
2
e
x
o
n
 
1
1
N
A
N
e
D
/
8
6
 
m
o
5
0
/
F
1
4
S
H
i
g
h
1
0
1
N
A
N
A
D
O
D
/
6
8
 
m
o
3
0
/
F
1
4
e
L
o
w
9
1
.
8
e
x
o
n
 
1
1
N
A
D
O
D
/
2
1
 
m
o
6
7
/
F
1
0
S
M
o
d
e
r
a
t
e
2
0
3
3
.
9
e
x
o
n
 
1
1
N
A
A
W
D
/
6
 
m
o
5
6
/
F
1
2
S
H
i
g
h
2
0
1
2
.
1
N
D
N
A
D
O
D
/
4
8
 
m
o
4
8
/
F
1
1
S
H
i
g
h
5
0
1
e
x
o
n
 
1
1
N
A
D
O
D
/
2
8
 
m
o
5
2
/
F
1
0
S
H
i
g
h
2
5
1
1
.
5
N
A
N
A
D
O
D
/
6
0
 
m
o
5
4
/
M
3
5
S
H
i
g
h
0
2
N
A
N
A
N
e
D
/
9
4
 
m
o
5
7
/
F
9
S
M
o
d
e
r
a
t
e
5
4
.
2
N
D
N
A
D
O
D
/
9
 
m
o
7
4
/
F
1
4
S
M
o
d
e
r
a
t
e
4
1
.
9
N
D
N
A
D
O
D
/
2
4
 
m
o
7
5
/
F
8
S
M
o
d
e
r
a
t
e
1
0
2
.
7
N
D
N
A
N
A
G
o
h
 
B
K
p
 
 
e
t
 
a
l
2
7
5
7
/
F
2
2
S
H
i
g
h
.
1
0
N
A
N
A
N
A
A
W
D
/
4
2
 
m
o
F
u
e
r
t
e
s
 
J
 
 
e
t
 
a
l
3
3
4
1
/
M
1
3
M
i
x
e
d
M
o
d
e
r
a
t
e
6
4
0
N
A
Y
e
s
N
e
D
/
2
4
 
m
o
V
i
j
 
M
 
e
t
 
a
l
2
8
9
 
c
a
s
e
s
N
A
N
A
N
A
N
A
N
A
N
A
N
A
N
A
r
u
i
z
-
T
o
v
a
r
 
J
 
 
e
t
 
a
l
2
9
3
 
c
a
s
e
s
N
A
N
A
N
A
N
A
N
A
N
A
1
 
p
a
t
i
e
n
t
 
r
e
c
e
i
v
e
d
 
 
t
r
e
a
t
m
e
n
t
A
W
D
/
1
2
 
m
o
B
a
r
r
e
d
a
 
 
B
o
l
a
n
o
s
 
F
 
 
e
t
 
a
l
1
5
1
7
 
c
a
s
e
s
.
1
0
 
(
1
6
 
c
a
s
e
s
)
N
A
H
i
g
h
 
(
2
 
c
a
s
e
s
)
 
L
o
w
 
(
3
 
c
a
s
e
s
)
N
A
N
A
N
A
2
 
c
a
s
e
s
1
 
A
W
D
/
2
9
 
m
o
 
1
 
A
W
D
/
6
0
 
m
o
p
r
e
s
e
n
t
 
c
a
s
e
 
 
2
0
1
1
3
9
/
M
7
.
5
S
L
o
w
5
5
7
N
O
N
e
D
/
2
4
 
m
o
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
S
,
 
s
p
i
n
d
l
e
;
 
e
,
 
e
p
i
t
h
e
l
i
o
d
;
 
N
A
,
 
n
o
t
 
a
v
a
i
l
a
b
l
e
;
 
N
e
D
,
 
n
o
 
e
v
i
d
e
n
c
e
 
d
i
s
e
a
s
e
;
 
m
o
,
 
m
o
n
t
h
;
 
A
W
D
,
 
a
l
i
v
e
 
w
i
t
h
 
d
i
s
e
a
s
e
;
 
D
O
D
,
 
d
e
a
d
 
o
f
 
d
i
s
e
a
s
e
;
 
N
D
,
 
n
o
t
 
d
o
n
e
;
 
L
I
,
 
l
a
b
e
l
i
n
g
 
i
n
d
e
x
.Casella et al
194  Clinical Medicine Insights: Oncology 2012:6
inhomogeneous,  sometimes  with  calcification  and 
necrosis.  Malignant  forms  can  be  described  like 
large lesions (.10 cm) with wall invasion or hepatic 
metastasis.52  Radiological  findings  in  EGSTs  are 
often similar to those of other retroperironeal tumors 
(sarcomas, malignant fibrous histiocytoma, liposar-
coma, leiomyosarcoma, fibrosarcoma).12,50,51 In our 
case the CT scan showed a periaortic mass (diameter 
6 × 6 × 8 cm). The retroperitoneal mass was placed 
in the paravertebral region, level L3–L4, on the left 
side of the aorta, in front of the left ilio-psoas muscle 
adherent to it. The lesion showed heterogeneous and 
persistent enhancement even in scans acquired in 
the late phase after administration of contrast. No 
adenopathies or local infiltration were found (Fig. 1). 
  Contrary to what was reported by other authors12 the 
CT-scan did not show in our case the presence of 
peripheral  calcifications  or  central  necrosis.  The 
biopsy eco- or CT-guided help to plan the best treat-
ment, and risk of peritoneal dissemination is negli-
gible.7  Limitations  of  pre-operative  image-guided 
FNA may be caused by inadequate sampling of the 
target mass lesion, as in our case, or by the difficulty 
in performing a mitotic count on aspiration cytology 
smears.7 The microscopic evaluation in the case we 
studied  showed  a  neoplastic  cellular  proliferation 
composed of spindle cells by type. The immunohis-
tochemical study showed positive for CD117, and 
focal positivity for S-100 protein and NSE, negative 
for CD34, smooth muscle and skeletal actin (Fig. 2). 
Surgical removal is the gold standard treatment for 
non metastatic EGISTs.7,11,15,48,53,54 Adjacent organs 
adherent to the mass should be resected en bloc with 
the  tumor,  in  order  to  avoid  capsule  rupture  and 
intra-abdominal spillage7,11,15,53–55 Laparoscopic sur-
gery should be avoided in large tumors because of 
the high risk of tumor rupture and consequent peri-
toneal seeding. A laparoscopic resection might be 
accepted  in  case  of  small  tumors  (,2–5  cm).55,56 
Prognostic factors in the case of EGISTs are not well 
encoded  in  the  literature.4,13–15,18,27–32  The  location, 
size,  cellularity,  mitotic  activity  and  necrosis  are 
reported to be the most accurate   predictors of a poor 
outcome.4,16,18,30,44  Omental  EGISTs  have  a  better 
prognosis than those in the mesenteric location.45 In 
respect to GIST size, it is g  enerally accepted as one 
of the main prognostic factors (low risk cut off ,5 cm 
in  diameter),16  although  other  authors15  found  no 
correlation between tumor size and survival. Some 
authors15 have reported a shorter survival in patients 
younger than 50 years. Ruiz-Tovar et al29 revealed in 
a    multivariate  analysis  that  masculine  gender, 
  constitutional    syndrome,  abdominal  mass  at 
  diagnosis, small bowel and retroperitoneum   location 
and actin-  negative tumors are bad p  rognostic fac-
tors. High cellularity, mitotic activity (.2 mitoses/50 
HPF) and the presence of necrosis are significantly 
associated with an adverse outcome.18 For Barreda-
Bolanos et al15 the low mitotic index associated with 
metastases did not reflect a good prognosis of dis-
ease. On the basis of a combination of the mitotic 
rate and MIB-1 labeling index, three risk categories 
can be identified: the high-risk group (5/50 HPF 
with  10%  Ki-67);  the  intermediate-risk  group 
(5/50  HPF  with  ,10%  Ki-67,  or,  ,5/50  HPF 
with 10% Ki-67), and the low-risk group (,5/50 
HPF  with  ,10%  Ki-67).4  The  exon  11    mutation 
causes a more aggressive biological behavior.16,22,26 
In our case, morphological and immunohistochemi-
cal features of tumor leaded to a diagnosis of EGIST 
as an intermediate risk form according to the risk 
assessment proposed by Fletcher et al16 and a low 
risk form according to risk assessment proposed by 
Yamamoto  et  al.4  The  introduction  of  drugs  that 
inhibit tyrosine kinase activity of receptors (imatinib 
mesylate) has resulted in a significant increase in 
s  urvival from 18 to 60 months in patients with mes-
enchymal tumors with mutations of the KIT gene in 
advanced stage.57
At present, there is no consensus in the literature 
about  the  use  of  imatinib  mesylate  as  standard 
treatment for patients with localized cancer KIT.11,13 
A  randomized  study  showed  that  administration 
of  these  drugs  for  a  period  of  one  year  prolongs 
relapse free-survival in localized tumors with KIT, 
completely removed, with diameter .3 cm, when 
compared  with  placebo.59  The  use  of  imatinib 
mesylate is recommended for 1 year in patients 
with  KIT  resectable  at  high  risk  of  recurrence.59 
Li et al13 have also shown that adjuvant imatinib can 
improve 1-, 2- and 3-years relapse-free survival rates 
in patients at intermediate or high risk of recurrence 
after complete tumor resection.
Not all authors who describe the EGISTs of  the 
retroperitoneum reported the use of imatinib mesy-
late after surgery (Table 1). Our patient underwent eGIST of retroperitoneum
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a  R0  section  and  the  tumor  was  classified  as  an 
intermediate and low-risk according to the classifica-
tion of Fletcher et al16 and Yamamoto et al4 respec-
tively, and therefore there was no need to proceed with 
the use of imatinib mesylate. The mean follow-up of 
patients reported in several case studies often do not 
exceed 24 months and this could lead to bias. Our 
patient is alive and disease free at 24 months after 
surgery.
In  summary,  CD117  positive  stromal  tumors, 
although extremely rare, can involve retroperitoneum. 
This  should  be  considered  when  imaging  studies 
reveal an abdominal tumor involving the retroperi-
toneum without a connection to the gastrointestinal 
tract. In most cases a preoperative diagnosis is not 
possible. Complete surgical removal of the mass and, 
when possible, “en bloc” with contiguous tissues and 
regional lymph nodes, is the gold standard therapy for 
non metastatic EGISTs. There is no consensus about 
the use of inhibitors of receptors of tyrosine kinase 
activity  in  these  tumors.  More  studies  are  neces-
sary to evaluate the role of molecular biology in tar-
geted therapy. It is difficult to assess their malignant 
potential and their overall prognosis although some 
Authors4,16 reported criteria that appear to be useful in 
predicting the risk of recurrence.
As  a  result  of  the  rarity  of  reports  of  primary 
EGISTs of retroperitoneum we need to analyze the 
data of reported cases in the literature in order to gain 
a better understanding about the pathogenesis, clini-
copathological features, prognosis and optimal treat-
ment of this disease.
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